Press releases
2020
July 30, 2020
Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division
July 23, 2020
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products
July 9, 2020
Grifols starts commercializing TAVLESSE® in Europe, diversifying its medicines portfolio
May 7, 2020
Grifols reinforces its liquidity position to EUR 1,700 million
March 27, 2020
Grifols and Shanghai RAAS close their strategic alliance in China
2019
December 6, 2019
Grifols presents its latest Alzheimer’s clinical trial data
December 4, 2019
Grifols introduces its first plasma protein-based biosurgery product
October 29, 2019
Grifols increases its revenues by 14.5% to EUR 3,738 million
July 16, 2019
Grifols presents additional encouraging Alzheimer’s trial results at AAIC
January 23, 2019
Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals
2017
2016
2015
November 6, 2015
The intermediate results from the Grifols AMBAR study support its continuation
October 28, 2015
Grifols agrees long term loan with the European Investment Bank
May 29, 2015
Grifols non-profit Ebola initiative (in Spanish version)
March 4, 2015
Grifols to make a major equity investment in Alkahest
2014
September 19, 2014
Grifols acquires 50% of the share capital of Kiro Robotics for 21 million euros
July 31, 2014
Grifols' net profit rises by 23% to 224.8 million euros in the First Half of 2014
May 30, 2014
Grifols sets payout at 40% of consolidated net profit
May 6, 2014
Grifols' net profit rises by 32.9% to 121.0 million euros in the First Quarter of 2014
May 3, 2014
Grifols opens new plasma fractionation plant in Spain
March 17, 2014
Grifols average cost of debt below 3.5% after a reduction of more than 2 points
February 27, 2014
Grifols' sales rose by 4.6% to Euros 2,741.7 million
2013
December 17, 2013
Shareholders endorse Grifols' Growth strategy
November 11, 2013
Grifols to acquire a Novartis diagnostics business unit for US$1,675 million
July 31, 2013
Grifols' net profit rose by 36.9% to 183 million euros in the first half of 2013
July 15, 2013
Moody's upgrades Grifols' credit ratings with stable outlook
May 24, 2013
Grifols holds its Ordinary General Shareholders' Meeting
May 14, 2013
Grifols officially inaugurates new immunoglobulin plant in the United States
May 2, 2013
Grifols' Net Profit Rises by 34.8% to 91 million Euros in the First Quarter of 2013
March 4, 2013
Grifols acquires 60% of the capital of biotechnology firm Progenika Biopharma
February 28, 2013
Grifols' sales increased by 46% to 2.620 million euros in 2012
2012
December 4, 2012
Grifols' shareholders approve bonus share issue as a remuneration formula
September 19, 2012
Grifols' Comprehensive Research Strategy in Alzheimer
August 1, 2012
Standard & Poor's Upgrades Grifols' Credit Rating
July 31, 2012
Grifols' sales increase by 15.2% to 1,316.7 million euros in the 1H 2012
July 9, 2012
Moody's upgrades Grifols' Credit Rating and changes Outlook to Positive
May 24, 2012
Grifols holds its Ordinary General Shareholders' Meeting
2011
December 2, 2011
Grifols' shareholders approve bonus share issue as a remuneration formula
October 28, 2011
Grifols calls Extraordinary General Shareholders' Meeting
July 28, 2011
Grifols sales in the first half of 2011 increase 30.2%
May 24, 2011
Grifols holds its General Ordinary Shareholders Meeting
May 5, 2011
Grifols´ sales grow 10.0% to 261.4 million Euros in the first quarter of 2011
May 5, 2011
Grifols´ sales grow 10.0% to261.4 million Euros in the first quarter of 2011
February 24, 2011
Grifols' turnover increased by 8.5% in 2010 to 990.7 million euros
February 18, 2011
Grifols starts construction of a new plasma fractionation plant in Barcelona
January 13, 2011
Grifols closes 1.1 billion dollar bond issue
2010
December 15, 2010
Grifols obtains EMA license to market its Flebogamma® DIF at 10% concentration
November 23, 2010
Grifols announces US launch of Flebogamma DIF 10% IVIG
November 22, 2010
Grifols Announces US Launch of Flebogamma® 10% DIF IVIG
November 4, 2010
Grifols´ turnover increased by 7.1% in the first nine months of 2010 to 738.8 MM
September 28, 2010
Grifols continues investing to boost its Diagnostic division
September 27, 2010
Grifols continues investing to boost its Diagnostics division
September 2, 2010
Grifols obtains FDA license in the US market for its IVIG Flebogamma
July 29, 2010
At 487.8 million Euros, Grifols sales in the first half of 2010 increase 3.7%
July 29, 2010
Grifols sales in the first half of 2010 increase 3.7% up to 487.8 million Euros
July 20, 2010
Grifols obtains its first crédit rating from Standard & Poor's and Moody's
June 24, 2010
Progenika Biopharma grants Grifols Worldwide distribution of its Bloodchip
June 24, 2010
Progenika Biopharma grants Grifols World-wide distribution of its Bloodchip
June 21, 2010
Grifols holds its Annual General Meeting
June 21, 2010
Grifols holds its Annual General Meeting
February 25, 2010
Grifols' net profit increased by 21.6% in 2009 to 148 MM euros
February 25, 2010
Grifols' net profit increased by 21.6% in 2009 to 148 MM euros
2009
December 23, 2009
Grifols obtains FDA approval for a new in filling area in its Albumin plant in LA
December 23, 2009
Grifols obtains FDA approval for new sterile albumin filling plant in Los Angeles
December 9, 2009
Grifols builds a new solutions factory in Murcia
October 26, 2009
Spanish minister of Industry, Tourism and Trade visits Grifols' facilities in LA.
October 16, 2009
Grifols to break ground on a new testing laboratory in San Marcos, Texas (US).
October 7, 2009
Grifols completes its USD600 million corporate bond issue in the US
September 21, 2009
Grifols publishes interim results of its clinical trial on Alzheimer's disease
September 21, 2009
Grifols publishes interim results of its clinical trial on Alzheimer's disease
July 29, 2009
Grifols' net profit rose 31.4% in the first half of 2009 to 81.7 MM euros
July 27, 2009
Grifols' net profit rose 31.4% in the first half of 2009 to 81.7 MM euros
June 30, 2009
Health Robotics and Grifols sign a collaboration agreement
June 30, 2009
Grifols gets a minority stake in Cardio3 BioSciences
June 30, 2009
Health Robotics and Grifols sign a collaboration agreement
June 21, 2009
Grifols holds its Annual General Meeting
June 11, 2009
Grifols promotes European research into liver cirrhosis
May 28, 2009
The shares of Grifols will be traded in the United States through ADRs
May 26, 2009
Cerus and Grifols Extend INTERCEPT Blood System Distribution to Italy
April 28, 2009
Grifols' net profit rose 33.8 % in the first quarter of 2009 to 41.6 million euros
February 26, 2009
Grifols' net profit advanced 38.7% in 2008 to 121.7 million euros.
January 28, 2009
Grifols Academy of Plasmapheresis opens in US
January 28, 2009
Grifols Academy of Plasmapheresis opens in US
January 19, 2009
Grifols gets a minority stake in Cardio3 BioSciences
2008
October 30, 2008
Grifols boosts nine-month net profit by 43% to 92.8 million euros
October 14, 2008
Grifols obtains marketing licence for its Intravenous Immunoglobulin Flebogamma
October 14, 2008
Flebogamma® DIF receives licensing in Australia
August 27, 2008
Grifols´ net profit rose 36.8% in the first half of 2008 to 62.2 million euros
August 27, 2008
Grifols' net profit rose 36.8% in the first half of 2008 to 62.2 million euros
June 13, 2008
Grifols holds its Ordinary General Meeting of Shareholders
June 10, 2008
Grifols signs an agreement with Gambro Renal Products (GRP) for MARS
May 26, 2008
Grifols obtains syndicated financing for 350 million euros
May 26, 2008
Grifols obtains syndicated financing for 350 million euros
May 14, 2008
Grifols' net profit rose 33% in the first quarter of 2008 to 31.1 million euros
May 14, 2008
Grifols' net profit rose 33% in the first quarter of 2008 to 31.1 million euros
May 10, 2008
Grifols signs an agreement with Gambro Renal Products (GRP) for MARS
May 7, 2008
Grifols obtains FDA licence for new filling area at its plasma products plant in the USA
May 6, 2008
Grifols obtains FDA licence for new filling area at its plasma products plant in the USA
April 23, 2008
Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement
April 23, 2008
Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement
April 15, 2008
Grifols signs a new distribution agreement with CDEX for Spain, Portugal and Italy
April 15, 2008
Grifols signs a new distribution agreement with CDEX
February 28, 2008
Net profits for Grifols increased 93.4% in 2007 to reach 87.8 million euros
February 28, 2008
Net profits for Grifols increased 93.4% in 2007 to reach 87.8 million euros
2007
December 11, 2007
The TAC incorporates Grifols into the Ibex-35
October 30, 2007
Grifols to announce Capital Investment Plan for 400 million over the next five years
October 22, 2007
Grifols and Laboratorios Divasa sign a strategic cooperation agreement
August 28, 2007
Grifols obtains EMEA authorization for sale of new generation IVIG in Europe
June 20, 2007
Grifols holds its Ordinary General Meeting of Shareholders
May 10, 2007
Grifols' turnover reaches 182 million euros in the first quarter of 2007
May 4, 2007
Grifols will manage 4 new plasma centers in the United States
March 22, 2007
Grifols R&D is qualified as excellent in the Profarma Plan 2006 meeting
February 26, 2007
Grifols reports a 23.8 increase in sales in 2006
2006
December 27, 2006
Grifols licensed by the FDA to market a new generation of IGIV in the United States
November 6, 2006
Grifols reports a 23.7% increase in sales in the first nine months of 2006
July 25, 2006
Grifols' Diagnostic division launches new in vitro diagnosis line
June 19, 2006
Grifols signs an agreement with Kardex Remstar for Latin America
May 16, 2006
Grifols sets offer price at €4.4 per share. The offering is 10 times oversubscribed
April 5, 2006
Grifols holds its General Shareholders Meeting
March 2, 2006
Grifols closes out 2005 with a 15% increase in turnover
Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.